Pinealon
Last reviewed 2026-10-30
Our read Opinion
Published evidence is mainly experimental hypoxia and cell research. Established clinical benefit, long-term safety and a US compounding clearance were not verified.
- Type
- Research-only / unapproved
- Regulatory status
- No FDA approval; foreign authorization unverified
- Compounding status
- Unclear / not listed
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- —
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support brain health and memory
- —Claimed to slow biological aging
A Glu-Asp-Arg tripeptide studied for neuronal resistance to hypoxic and oxidative stress. Proposed effects include modulation of antioxidant defenses and excitotoxicity.
No FDA approval or EMA authorization was identified for Pinealon. Supplement or bioregulator marketing does not establish authorization as a therapeutic drug.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
The neuroprotection story is preclinical rather than an established treatment. Human benefit should remain a hypothesis until credible controlled trials demonstrate it.
No news yet for this peptide.
Slowing biological aging: telomeres, sleep/circadian rhythm and brain aging.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.